Vivace Therapeutics disclosed preclinical efficacy for VT‑3989, a TEAD inhibitor that suppressed aggressive NF2‑deficient tumor growth in vitro and in vivo (68e05edcb0400dd1). The company showed activity across meningioma models and reports plans for early clinical development in advanced solid tumors. The main result: VT‑3989 impaired proliferation and reduced tumor volume in NF2-mutant xenografts, supporting TEAD as a therapeutic node in Hippo pathway–driven cancers. Vivace frames VT‑3989 as advancing into early clinical testing for patients lacking effective targeted options. For oncology drug developers, VT‑3989 exemplifies prioritization of transcriptional cofactor inhibition (TEAD) against lineage‑specific tumor drivers—an approach that may unlock therapies for genetically defined, previously undruggable cohorts.